Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Stankovic Srdjan R.	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President
(Last)          (First)          (Middle) C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, STE. 300	3. Date of Earliest Transaction (MM/DD/YYYY) 6/18/2020
(Street) SAN DIEGO, CA 92130 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/18/2020		M		8551	A	$19.65	19885	D
Common Stock	6/18/2020		M		17494	A	$19.98	37379	D
Common Stock	6/18/2020		M		39798	A	$18.12	77177	D
Common Stock	6/18/2020		S(1)		65843	D	$50.0088 (2)	11334	D
Common Stock	6/19/2020		M		16452	A	$18.12	27786	D
Common Stock	6/19/2020		S(1)		16452	D	$50.1164 (3)	11334	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$19.65	6/18/2020		M			8551	(4)	3/14/2026	Common Stock	8551	$0.00	0	D
Employee Stock Option (Right to Buy)	$19.98	6/18/2020		M			17494	(5)	4/17/2028	Common Stock	17494	$0.00	34112	D
Employee Stock Option (Right to Buy)	$18.12	6/18/2020		M			39798	(6)	11/18/2028	Common Stock	39798	$0.00	110202	D
Employee Stock Option (Right to Buy)	$18.12	6/19/2020		M			16452	(6)	11/18/2028	Common Stock	16452	$0.00	93750	D

Explanation of Responses:
(1)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019.
(2)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.175, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(3)	were sold in multiple transactions at prices ranging from $50.00 to $50.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
(4)	The stock option is fully vested and exercisable.
(5)	25% of the shares subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(6)	25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Stankovic Srdjan R. C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, STE. 300 SAN DIEGO, CA 92130			President

Signatures
/s/ Austin D. Kim, Attorney-in-Fact		6/19/2020
**Signature of Reporting Person		Date